Search

Your search keyword '"Honda,Takuya"' showing total 1,022 results

Search Constraints

Start Over You searched for: Author "Honda,Takuya" Remove constraint Author: "Honda,Takuya"
1,022 results on '"Honda,Takuya"'

Search Results

1. Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel

2. A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreatic cancer

4. Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel

5. Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the NAPOLEON study

6. Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer

7. C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel

16. Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab–paclitaxel or FOLFIRINOX: A post–hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study)

17. Gemcitabine plus nab-paclitaxel in older patients with metastatic pancreatic cancer: A post-hoc analysis of the real-world data of a multicenter study (the NAPOLEON study)

18. Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: A multicenter retorospective ovservational study (NAPOLEON-2)

19. A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study

23. Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: A multicenter retrospective observational study (NAPOLEON-2)

24. The effect of our physical or cognitive program for the elderly with mild cognitive impairment: the eighteen months’ follow‐up after intervention, third version, showed an improvement in RBMT story retention delayed and Raven’s colored progressive matrices

25. Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel

26. PIVKA‑II is associated with liver function, bone metabolism, and muscle function in patients with liver disease

27. Correction to: A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study

29. Impact of single-heterozygous UGT1A1 on the clinical outcomes of irinotecan monotherapy after fluoropyrimidine and platinum-based combination therapy for gastric cancer: a multicenter retrospective study

31. Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Observational Study (NAPOLEON Study)

34. Examination of the Effect of Proton Pump Inhibitors on the Anticancer Activity of Oxaliplatin

36. First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients with advanced gastric cancer: a multicenter propensity score matched study

38. C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel

40. Miglustat, a glucosylceramide synthase inhibitor, mitigates liver fibrosis through TGF-β/Smad pathway suppression in hepatic stellate cells

42. Multicenter Retrospective Analysis of Original versus Modified FOLFIRINOX in Metastatic Pancreatic Cancer: Results of the NAPOLEON Study

45. P74-4 FOLFOXIRI+a is an ideal regimen for conversion in the treatment of advanced/recurrent colorectal cancer

47. Tankyrase Regulates Neurite Outgrowth through Poly(ADP-ribosyl)ation-Dependent Activation of β-Catenin Signaling

48. Two-particle Bose–Einstein correlations in pp collisions at √s=13 TeV measured with the ATLAS detector at the LHC

49. Additional file 1 of Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab���paclitaxel or FOLFIRINOX: A post���hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study)

50. Additional file 2 of Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab���paclitaxel or FOLFIRINOX: A post���hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study)

Catalog

Books, media, physical & digital resources